Latest Research And Development News

Lumos Diagnostics reported a 6% revenue increase to US$13.2 million for FY26, driven by an 875% surge in FebriDx® sales following a pivotal CLIA waiver. The company expanded U.S. adoption to 170+ healthcare sites and secured milestone payments exceeding US$6 million.

Proteomics International Laboratories has streamlined operations, secured a key US patent for its endometriosis test, and inked a three-year exclusive distribution deal with Healius for its Promarker diagnostics in Australia.

Energy Action Limited's unaudited FY26 results show a sharp profit decline to $0.45 million on stable revenue of $12.2 million, weighed down by lower R&D incentives and higher costs.

Janus Electric has locked in A$7.7 million through a private placement to bolster its growth in the North American electric heavy vehicle market, following a surge in orders.

Zeotech completed a 110-hole drilling campaign at Toondoon, secured key approvals, progressed AusPozz™ commercial trials, and demonstrated a 92% methane reduction in landfill trials.

Argenica Therapeutics is gearing up for a pivotal late-stage clinical trial of its neuroprotective drug ARG-007 (xaranetide) in acute ischaemic stroke, backed by strong safety assays and solid funding.

Invex Therapeutics has broadened its preclinical Alzheimer's program with Tessara Therapeutics, while its cash reserves dipped to $4.02 million in Q4 FY26 amid increased research and administrative costs.

Nimy Resources advances gold exploration with new priority targets and secures funding to pioneer gallium processing research at its Mons Project in Western Australia.

Australian Gold and Copper Ltd (ASX: AGC) has completed the second tranche of its $5 million placement, received a nearly $1 million R&D tax refund, and finalized the acquisition of the drill-ready Junee gold project in NSW.

Spenda Limited anticipates a significant R&D tax offset exceeding AUD 1.75 million for FY26, providing a timely cash boost amid its push towards cash-flow neutrality.

PainChek has received a $1.123 million R&D tax incentive refund for FY2025, reinforcing its cash reserves and underpinning ongoing development of AI pain assessment algorithms and US market validation.

Noxopharm reported significant progress in its Sofra technology, highlighting enhanced cancer drug potential and preparations for a US FDA clinical trial, while managing tight cash reserves.